Last reviewed · How we verify

Intra-Abdominal Anaerobic Abscess — Treatment Landscape & Competitive Intelligence

Intra-Abdominal Anaerobic Abscess (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Intra-Abdominal Anaerobic Abscess, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cleocin T CLINDAMYCIN PHOSPHATE Pfizer Lincosamide Antibacterial 1972-01-01
Cleocin clindamycin Generic (originally Upjohn/Pfizer) Lincosamide antibiotic 50S ribosomal protein L10 1970-01-01
Metro I.V. In Plastic Container METRONIDAZOLE Baxter Nitroimidazole Antimicrobial [EPC] 1963-01-01
Metronidazol Metronidazol University of Oslo Thioredoxin reductase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Baxter · 1 drug in Intra-Abdominal Anaerobic Abscess
  2. Generic (originally Upjohn/Pfizer) · 1 drug in Intra-Abdominal Anaerobic Abscess
  3. Pfizer · 1 drug in Intra-Abdominal Anaerobic Abscess
  4. University of Oslo · 1 drug in Intra-Abdominal Anaerobic Abscess

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Intra-Abdominal Anaerobic Abscess:

Cite this brief

Drug Landscape (2026). Intra-Abdominal Anaerobic Abscess — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/intra-abdominal-anaerobic-abscess. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing